Carcinomatous meningitis related to patients with breast cancer patients: A new approach of an individual treatment regimen with liposomal cytarabine.

Abstract Background Recent years, attributed to early detection and new therapies, the mortality rates of breast cancer (BC) decreased. Nevertheless, the global prevalence was still high and the underlying molecular mechanisms were remained largely unknown. The investigation of prognosis-related genes as the novel biomarkers for diagnosis and individual treatment had become an urgent demand for clinical practice. Methods Gene expression profiles and clinical information of breast cancer patients were downloaded from The Cancer Genome Atlas (TCGA) database and randomly divided into training (n = 514) and internal validation (n = 562) cohort by using a random number table. The differentially expressed genes (DEGs) were estimated by Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. In the training set, the gene signature was constructed by the least absolute shrinkage and selection operator (LASSO) method based on DEGs screened by R packages. The results were further tested in the internal validation cohort and the entire cohort. Moreover, functions of five genes were explored by MTT, Colony-Formation, scratch and transwell assays. Western blot analysis was used to explore the mechanisms. Results In the training cohort, a total of 2805 protein coding DEGs were acquired through comparing breast cancer tissues (n = 514) with normal tissues (n = 113). A risk score formula involving five novel prognostic associated biomarkers (EDN2, CLEC3B, SV2C, WT1 and MUC2) were then constructed by LASSO. The prognostic value of the risk model was further confirmed in the internal validation set and the entire set. To explore the biological functions of the selected genes, in vitro assays were performed, indicating that these novel biomarkers could markedly influence breast cancer progression. Conclusion We established a predictive five-gene signature, which could be helpful for prognosis assessment and personalized management in breast cancer patients.

Download Full-text

Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies

Breast Care ◽

10.1159/000486330 ◽

2018 ◽

Vol 13 (1) ◽

pp. 22-26

Author(s):

Florian Schütz ◽

Frederik Marmé ◽

Christoph Domschke ◽

Christof Sohn ◽

Alexandra von Au

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

New Technologies ◽

Breast Cancer Patients ◽

New Approach ◽

Tumor Associated Antigen ◽

Specific Tumor ◽

Car T ◽

Passive Vaccination ◽

Near Future

Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is a promising strategy, especially in tumors that have a specific tumor-associated antigen. Although cellular immunotherapies have not yet shown efficacy, new technologies are on the way to improve this approach. Given the recent Food and Drug Administration approval of chimeric antigen receptor (CAR) T cells for leukemia, it is only a question of time before solid tumors will follow. However, not all breast cancer patients will respond to cellular or other immunotherapy. Hence, we must define subpopulations of breast cancer patients who benefit from this new approach.

Download Full-text

Treatment regimen, sexual attractiveness concerns and psychological adjustment among African American breast cancer patients

Psycho-Oncology ◽

10.1002/pon.616 ◽

2002 ◽

Vol 11 (6) ◽

pp. 505-517 ◽

Cited By ~ 33

Author(s):

Kathryn L. Taylor ◽

Ruth M. Lamdan ◽

Jamie E. Siegel ◽

Rebecca Shelby ◽

Mary Hrywna ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

Cancer Patients ◽

Treatment Regimen ◽

Psychological Adjustment ◽

Sexual Attractiveness ◽

Breast Cancer Patients

Download Full-text

460 PUBLICATION The significance of chemotherapy in the treatment of carcinomatous meningitis in breast cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80757-8 ◽

2005 ◽

Vol 3 (2) ◽

pp. 129

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Carcinomatous Meningitis ◽

Breast Cancer Patients

Download Full-text

New Approach to Predict Bone Metastasis in Breast Cancer Patients

Oncology Times ◽

10.1097/01.cot.0000796316.91619.45 ◽

2021 ◽

Vol 43 (S19) ◽

pp. 23-23

Author(s):

Catlin Nalley

Keyword(s):

Breast Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Breast Cancer Patients ◽

New Approach

Download Full-text

A glycolysis-related gene expression signature in predicting recurrence of breast cancer

10.21203/rs.3.rs-27021/v1 ◽

2020 ◽

Author(s):

Jianing Tang ◽

Gaosong Wu

Keyword(s):

Breast Cancer ◽

Gene Expression ◽

High Risk ◽

Cancer Patients ◽

Risk Group ◽

Gene Signature ◽

Low Risk ◽

Individual Treatment ◽

Breast Cancer Patients ◽

Related Gene

Abstract Background Metabolic change is the hallmark of cancer. Even in the presence of oxygen, cancer cells reprogram their glucose metabolism to enhance glycolysis and reduce oxidative phosphorylation. In the present study, we aimed to develop a glycolysis-related gene signature to predict the prognosis of breast cancer patients.Methods Gene expression profiles and clinical data of breast cancer patients were obtained from the GEO database. Univariate, Lasso-penalized, and multivariate Cox analysis were performed to construct the glycolysis-related gene signature.Results A four-gene based signature (ALDH2, PRKACB, STMN1 and ZNF292) was developed to separate patients into high-risk and low-risk groups. Kaplan-Meier survival analysis demonstrated that patients in low-risk group had significantly better prognosis than those in the high-risk group. Time-dependent ROC analysis demonstrated that the glycolysis-related gene signature had excellent prognostic accuracy. We further confirmed the expression of the four prognostic genes in breast cancer and paracancerous tissues samples using qRT-PCR analysis. Expression level of PRKACB was higher in paracancerous tissues, while STMN1 and ZNF292 were overexpressed in tumor samples. No difference was found in ALDH2 expression. The same results were observed in the IHC data from the human protein atlas. Global proteome data of 105 TCGA breast cancer samples obtained from the Clinical Proteomic Tumor Analysis Consortium were used to evaluate the prognostic value of their protein levels. Consistently, high expression of PRKACB protein level was associated with better prognosis, while high ZNF292 and STMN1 protein expression levels indicated poor prognosis.Conclusions The glycolysis-related gene signature might provide an effective prognostic predictor and a new view for individual treatment of breast cancer patients.

Download Full-text

Survival of a cohort of 25 breast cancer patients with neoplastic meningitis treated with intrathecal liposomal cytarabine

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.1109 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 1109-1109

Author(s):

E. Le Rhun ◽

F. Zairi ◽

M. Baranzelli ◽

M. Faivre-Pierret ◽

P. Devos ◽

...

Keyword(s):

Breast Cancer ◽

Supportive Care ◽

Cancer Patients ◽

Systemic Chemotherapy ◽

Neurological Status ◽

Neoplastic Meningitis ◽

Liposomal Cytarabine ◽

Breast Cancer Patients ◽

Csf Cytology ◽

Median Delay

1109 Background: Neoplastic meningitis (NM) occurs in 5% of the patients with breast cancer; if untreated the median duration of survival is 5 weeks. Combination of intrathecal (IT), systemic chemotherapy, and supportive care may increase overall survival (OS) to 5 months (Chamberlain, 2005). Methods: 30 consecutive female breast cancer patients diagnosed with NM, on the basis of cerebrospinal fluid (CSF) cytology and/or cerebrospinal MRI with clinical symptoms, have been prospectively treated for 19 months. Three patients did not receive any treatment because of a poor neurological status at diagnosis; 2 patients stopped treatment because of the lack of improvement after 1.5 months. The aim was to report clinico-pathological characteristics and OS in patients treated with IT liposomal cytarabine and supportive care with or without systemic chemotherapy. Statistical analyses were performed in the 25 treated patients. Correlations between tumor characteristics and OS were analyzed using usual statistical methods (Kaplan Meier, Log-rank, Cox). Results: Median age at NM diagnosis was 56 years. Median Karnofsky Performance Status (KPS) was 75. Breast cancers were invasive ductal carcinoma in 75%. Estrogen and progesterone receptors were detected in respectively 64 and 40%. HER-2 hyperexpression was observed in 33.5%. Tumors were triple negative in 17%. At the time of NM diagnosis CSF cytology and cerebrospinal MRI were positive in respectively 64% and 87.5%. Brain metastases were present in 64% of the patients, 36% had whole brain radiotherapy. Median delay between first symptoms and diagnosis was 16 days. Median delay between NM diagnosis and first IT was 17 days. Systemic chemotherapy was given in 56.5% at the discretion of the referring oncologist. All patients had supportive care. After 5 IT a clinical stabilization or improvement was observed in 56.5%. A CSF response was observed in 36%. Median OS of treated patients was 7 months. KPS at diagnosis (≥80), neurological status after 5 IT were significantly correlated with OS. A trend was also observed between association with systemic chemotherapy and OS. Conclusions: Our results confirm that the association of IT, systemic treatment and supportive care treatment may be useful in treating this cancer complication. No significant financial relationships to disclose.

Download Full-text